Letter to the Editor
Lewis et al 1 identified 4 patients with a history of hepatic encephalopathy (HE) who received the nonsystemic antibiotic rifaximin as prophylaxis and developed a rifampinresistant Staphylococcus aureus infection. Rifaximin is a semisynthetic derivative of rifamycin SV, and the additional pyridoimidazole ring in its structure results in its nonsystemic profile. In the United States, rifaximin 550 mg tablets twice daily is indicated for reducing risk of overt HE recurrence in adults. Because antibiotic-resistant bacterial infections are a major concern, predisposing factors in a cirrhotic population are of particular interest. We thank the authors for reporting these 4 cases. However, the evidence provided does not allow one to conclude that rifaximin as HE prophylaxis played a role in the emergence of the rifampinresistant S aureus infections.
A high rate of bacterial antibiotic-resistant infections has been reported in US hospitalized patients with cirrhosis. Methicillin-resistant S aureus, identified in 2 of the 4 cases in Lewis et al, 1 can exhibit high rates of rifampin resistance, 3 and patients with HE may harbor more antibioticresistant organisms when compared with patients without HE, presumably because of previous exposure to systemic (conventional) antibiotics or other drugs and/or their underlying illness. Furthermore, a prospective multivariate analysis of hospitalized patients with cirrhosis indicated that nonsystemic antibiotic (rifaximin) exposure within 30 days was not associated with antibiotic-resistant bacterial infections (odds ratio = 0.4; 95% CI = 0.04-2.8; P = 0.3). 2 The overall safety profile of rifaximin has been well established during the past 30 years. Rifaximin is currently marketed in 47 countries and has been available since 1987 in Italy and since 2004 in the United States.
The Valentin et al 4 study cited by Lewis et al 1 was a pilot, nonrandomized trial (n = 11 individuals) that identified only 2 rifampin-resistant S aureus isolates. Lewis et al 1 failed to cite any large rifaximin trials evaluating antibiotic susceptibility of Staphylococcus isolates. One randomized, double-blind, placebo-controlled phase 3 trial (TARGET 3 [irritable bowel syndrome with diarrhea]) of rifaximin 1650 mg/d for up to three 2-week courses evaluated 1381 Staphylococcus isolates collected from 115 patients at various locations (ie, forearms, nostrils, palms of hands, and perianus) and times 5 ; of 71 S aureus isolates examined, none was resistant to rifampin, and no S aureus overgrowth was observed. The authors of that study concluded that rifaximin did not lead to resistance to rifampin or other antibiotics in Staphylococcus skin isolates.
